2019.Sep.16
Announcement of phase II clinical trial result for ovarian cancer on OBI and Mackay Memorial Hospital cooperated Adagloxad Simolenin, OBI-822
Date of occurrence of the event: Sep 16, 2019 Company name: OBI Pharma, Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: Not Applicable Cause of occurrence: Announced phase II clinical trial result for ovarian cancer on OBI and Mackay Memorial Hospital. Countermeasures: None Any other matters that […]
This article is password protected.
To view the content, please enter your password in the field below